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Dilated cardiomyopathy (DCM) is a relatively common condition in 
sub-Saharan Africa, accounting for a substantial portion of patients 
admitted for heart failure. In the Heart of Soweto study it was the 
most common cardiovascular disease.1 Two important contributions 
to our understanding of this puzzling condition appear in this issue.
The first paper2 examines the genetic background of ‘idiopathic 
cardiomyopathy’. Just over 25% of the patients had familial disease, 
with an autosomal dominant background in 72% of those, recessive 
inheritance in 17% and X-linked recessive inheritance in 10%. The 
clear message that emerges is the importance of making sure that 
otherwise unexplained cardiomyopathy is not familial and genetic 
in origin. The authors also state that the same holds for peripartum 
cardiomyopathy.
The second article3 analyses the clinical differences between the 
familial and non-familial types of DCM. The patients with idiopathic 
cardiomyopathy were apparently more ill with more symptoms, larger 
hearts and a trend to lower ejection fractions. However, death rates at 
the end of the median follow-up period were the same, at about 40%. 
The use of digoxin emerged as a significant predictor of mortality in 
the idiopathic but not in the familial group. Digoxin levels are not 
reported, and nor are plasma potassium levels, which are powerful 
modulators of the levels at which digoxin becomes toxic (Fig. 1). 
The 1997 DIG trial is often quoted in support of the use of digoxin.4 
However, those were ancient days in terms of the progress of heart 
failure therapy, well before widespread evidence-based use of the major 
mortality-reducing agents, namely beta-blockers and angiotensin-
converting enzyme (ACE) inhibitors, and long before interventions 
such as cardiac resynchronisation.5 The current approach to drug 
therapy for chronic heart failure is set out in Table I. 
Heart failure with sinus rhythm – 
swings in digoxin use 
Digitalis has gone through four phases.5 Historically it was regarded 
as essential first-line therapy for heart failure, together with the 
diuretics. Secondly, data on ineffectiveness or tolerance came in and 
use declined, especially in the UK. Thirdly, positive haemodynamic 
data in several small studies and the two major withdrawal studies 
then re-established the place of digoxin.  
Currently use is declining again for several reasons. Firstly, there 
are major disagreements about the ideal dose and blood levels.5 
Secondly, even in the large DIG trial, when heart failure therapy was 
relatively primitive and did not have the benefit of beta-blockade and 
ACE inhibitors, there were only limited benefits.4 Thirdly, the very 
narrow therapeutic-toxic window and numerous drug interactions 
(see Tables 6-6 and 6-7 in Faucier et al.5) have cast further doubt. 
Fourthly, and most tellingly, digoxin is not even considered safe 
as a last measure in patients with advanced heart failure referred for 
transplant evaluation.6 Patients received full contemporary therapy, 
almost all being treated by ACE inhibitors/ARBs and beta-blockers, 
with aldosterone blockers in 46% and devices in 71%. Patients 
were carefully matched for severity of disease with a control group 
not given digoxin, yet for the primary outcome of time to death, 
urgent transplantation or insertion of a device, the use of digoxin 
was associated with increased hazard, the ratio being 2.28 (95% 
confidence interval 1.51 - 3.43, p<0.001).
These many problems have relegated digoxin to an optional extra in the 
management of heart failure, given if at all in lower doses than previously, 
with the aim of achieving symptomatic rather than mortality benefit.
Heart failure and atrial fibrillation
In the second report in this issue,3 20 - 25% of patients had atrial 
fibrillation. How does that affect policy? Increased mortality persists.7 
In a single-centre study on 1 269 unselected consecutive patients with 
both atrial fibrillation and heart failure, therapy with a beta-blocker 
alone or a beta-blocker plus digoxin was associated with a similar 
decrease of just over 40% in the risk of death (p=0.005). Digoxin 
alone was associated with worse survival, similar to that of patients 
without any rate control treatment. There appears to be only one 
very small study (N=14) focusing on beta-blockade added to digoxin 
in the treatment of atrial fibrillation in idiopathic cardiomyopathy.8 
Carvedilol added to digoxin improved left ventricular function. 
Nonetheless, overall there is no clear place for digoxin in the therapy 
of heart failure and atrial fibrillation, and the only major study 
suggests that this drug increased mortality.7
Doses and blood levels of digoxin
These are reviewed elsewhere.6 Overall, the problem is that no well-
designed current studies have prospectively linked the digoxin dose to 
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Table I.  Chronic heart failure: Drugs that reduce mortality, 
improve symptoms, or might harm 
Reduce mortality – must try to use
1. ACE inhibitors or ARBs
2. Beta-blockers
3. Spironolactone or eplerenone (first check potassium, creatinine)
4. Isosorbide-hydralazine (well tested in African-Americans)
Improve symptoms – use according to clinical judgement
1. Diuretics
2. Nitrates
3. Iron for anaemia
4. Metabolically active agents (if available: trimetazidine, perhexiline)
May be harmful – use cautiously only after due consideration
1. Inotropes and inotropic dilators
2. Anti-arrhythmics, except beta-blockers and amiodarone
3. Calcium channel blockers
4. Digoxin, after checking levels of potassium and creatinine, only in 
low doses aiming at blood levels of 0.65 - 1.3 nmol/l (0.5 - 0 1.0 ng/
ml). High-dose digoxin, with blood levels of 1.3 - 2.6 nmpl/l (1.0 - 
2.0 ng/ml), was previously acceptable but no longer is  
Modified from Table 6-3 in Opie and Gersch.6
ACE = angiotensin-converting enzyme; ARBs = angiotensin-receptor blockers.
Fig. 1. The relationship between toxic digoxin levels and concurrent blood 
digoxin levels (modified from Fig. 6-10 in Opie and Gersch,6 p. 189). 
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Fig. 1. The relationship between toxic digoxin levels and concurrent blood digoxin levels 
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both blood levels and clinical outcome. There is now general agreement 
that the therapeutic-toxic window of digoxin is narrow. Previously, the 
ideal blood level was pragmatically regarded as 1 - 2 ng/ml (1.3 - 2.6 
nmol/l). Currently, lower doses and lower blood levels are strongly 
supported. Of note, low doses (0.125 mg daily) with a low blood level 
(mean 0.8 ng/ml) provide as much haemodynamic benefit as previously 
‘standard doses’ (0.25 mg daily, mean blood level 1.5 ng/ml), all this 
without impairing the autonomic effect as measured by heart rate 
variability. Digoxin withdrawal studies show that such low doses are as 
good as the higher doses in maintaining left ventricular function.  
Persuasive data come from a retrospective analysis of the large DIG 
trial on 3 782 heart failure patients followed up for 3 years.9 All-cause 
mortality was modestly decreased, albeit by only 6%, in the tertile 
with digoxin levels in the previously ‘low’ range  0.6 - 1.0 nmol/l. This 
reduction in deaths is more impressive in the propensity-matched 
re-analysis of the trial,10 which nonetheless could not get around the 
basic problem that this trial was done in days gone by, before treatment 
of heart failure required beta-blockers and ACE inhibitors.  
The next higher tertile of digoxin levels in the DIG trial (1.2 - 
1.4 nmol/l) had no effect on mortality, whereas the tertile with the 
previously accepted higher levels (1.6 nmol/l or more) was associated 
with a mortality increase of 12%.9
The practical message – a turnaround 
level
Digoxin therefore has bidirectional effects on mortality, with the 
‘turnaround’ level being about 1.3 nmol/l,10 giving a practical 
therapeutic range of 0.65 - 1.3 nmol/l (Fig. 1) and certainly no higher. 
Although this conclusion is based on imperfect data and is strictly 
speaking only hypothesis generating,11 we are unlikely to obtain more 
decisive data in the near future. To achieve the previous ‘therapeutic’ 
but now potentially toxic levels of 1.3 - 2.6 nmol/l, various nomograms 
have been designed to calculate the dose, taking into account lean 
body mass and renal function. Clearly these calculations will give too 
high a dose according to present standards. Note that all these depend 
on a normal plasma potassium level (Fig. 1). 
Digoxin cautions before use
Serum potassium and blood digoxin levels should be measured. 
However, potassium and creatinine levels are not reported in the 
accompanying study.3
•    Hypokalaemia predisposes to toxicity, and potassium must always 
be checked simultaneously with the digoxin level (Fig. 1).
•    Renal failure. Digoxin is excreted by the kidneys, so the plasma 
creatinine must be checked before use. A high circulating level 
means that caution is necessary and that digoxin, if used at all, 
should be at an even lower dose.  
Digoxin contraindications
Contraindications to digoxin are many and serious.5
•    The risk of digitalis toxicity is the major contraindication, pending 
a full history of digitalis dosage, blood tests for renal failure, and 
measurement of serum digoxin and potassium. Digoxin has a 
blood half-life of 36 hours, so toxicity is not readily reversed and 
requires digoxin antibodies, not widely available. 
•    Hypertrophic obstructive cardiomyopathy (hypertrophic sub-
aortic stenosis, asymmetrical septal hypertrophy) is a contraindication 
(unless there is atrial fibrillation and severe myocardial failure), 
because the inotropic effect can worsen outflow obstruction.
•    In some cases of Wolff-Parkinson-White syndrome with atrial 
fibrillation, digitalisation may accelerate anterograde conduction 
over the bypass tract to precipitate ventricular tachycardia or 
ventricular fibrillation.
•    Atrioventricular (AV) nodal heart block when significant. 
Intermittent complete heart block or second-degree AV block or 
sick sinus syndrome may be worsened by digitalis, especially if 
there is a history of Stokes-Adams attacks or when conduction is 
likely to be unstable, as in recent acute myocardial infarction with 
heart failure or acute myocarditis.
•    Heart failure with preserved ejection fraction (diastolic 
dysfunction), seen most notably with concentric ventricular 
hypertrophy as in hypertension or aortic stenosis, and associated 
with the paradox of a normal or high ejection fraction, does not 
respond to digitalis.
•    Fear of breast cancer. The digoxin molecule has similarities to 
the oestrogen receptor. Hence digoxin may bind to this receptor 
with the theoretical risk of increased breast cancer. This fear 
is confirmed in two large recent Danish studies making use of 
Danish population databases,12,13 both of which show an increased 
risk of breast cancer with digoxin use in women.
Conclusion
Before using digoxin, be fully convinced that this potentially lethal 
drug is essential. Why use digoxin for heart failure? Why use a drug 
with a narrow band of truly safe and effective blood levels? Why use a 
drug that has no positive hard outcome data in the modern era? Note 
that blood levels that were previously acceptable are now regarded 
as toxic. Also note that the patient on digoxin needs their potassium 
and creatinine levels to be monitored. Finally, it is safe to say that 
digoxin is a drug that would never be passed by the Food and Drug 
Administration if it was submitted for registration today. Put simply, 
digoxin is a dangerous drug, its use perhaps being excusable in earlier 
years when little was known about its dangers and we did not yet 
have today’s effective therapy for heart failure. The new prospective 
trials that would have been crucial have not been carried out. It is no 
wonder that increased mortality was associated with digoxin use in 
the second of the two studies in this issue of the SAMJ. 
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